News


Digital Proteomics at ASMS 2017
14 Jun 2017

Digital Proteomics at ASMS 2017

We just wrapped up another amazing ASMS in Indianapolis! If you missed us last week, we’ve uploaded the literature from our booth to the Literature page.  There you will find our poster on untargeted metabolomics analysis, including case studies for pharmacokinetics and metabolomics identification using Quorum.  You’ll also see a new case study on sequencing an unusual antibody sample containing one heavy chain and two...

Read More


Digital Proteomics at Peptalk 2017
13 Jan 2017

Digital Proteomics at Peptalk 2017

Natalie presented the latest development to Valens and Alicanto at Peptalk 2017.  Alicanto is our multi-omic approach to antibody discovery that integrates B-cell transcript sequencing with mass spectrometry-based analysis of serum antibodies.  The sequenced repertoire containing tens or hundreds of thousands of sequences is screened using the mass spectra to identify circulating antibodies.  Optimized proteomics protocol achieves high antibody coverage of the variable domain and distinguishes with high...

Read More


The most accurate de novo antibody sequencing service available, guaranteed
13 Sep 2016

The most accurate de novo antibody sequencing service available, guaranteed

Digital Proteomics and LakePharma Inc. announce the release of the next generation of de novo antibody sequencing service. The new service combines Digital Proteomics’ patented algorithm, Valens, with LakePharma’s expertise in antibody engineering and expression. The final deliverable is an antibody sequence with experimentally validated antigen binding. Without any prior knowledge of the sequence (no DNA required), the new service determines the primary sequences of...

Read More


Soil metaproteomics with ENOSI
03 Jun 2015

Soil metaproteomics with ENOSI

At ASMS 2015, we presented groundbreaking work in metaproteomics using our proteogenomic toolkit, ENOSI. Despite the lack of an accurate reference gnome for many of the species suspected in the proteomic sample, ENOSI was able to use RNA-seq data to identify variation in homologous genomes. Using only publicly available proteomic, transcriptomic, and genomic data, we were able to identify interesting peptides. Read the details on...

Read More


ENOSI version 1.2 is now available!
06 Apr 2015

ENOSI version 1.2 is now available!

A new version of Enosi is now available! Among the new features you’ll find the ability to resume a previous Enosi run from any stage, or aggregate the results from multiple ENOSI runs. In addition, transcript alignments can be provided in SAM or BAM format. The event-based results are also richer, with event type specific information such as the reference nucleotide for mutation events and...

Read More


Resurrecting monoclonal antibodies with VALENS
31 Mar 2015

Resurrecting monoclonal antibodies with VALENS

We presented the methodology behind our monoclonal antibody sequencing service, Valens at MSACL in San Diego. Armed with only the antibody protein and no genomic or transcriptomic information, Valens can recover the complete sequence of both the heavy and light chains. In addition, we can identify sites of liability, including those sites susceptible to oxidation and deamidation. Read the details on our poster


MOLECULAR NETWORKS helps map the human skin
30 Mar 2015

MOLECULAR NETWORKS helps map the human skin

Molecular Networks were key in the analysis of the human skin microbiome. A recent paper published in the Proceedings of the National Academy of Sciences led by Professor Pieter Dorrestein uncovers the complement and spatial relationships between molecules present on the human body. While only a small set of these molecules were well characterized before the study, Molecular Networks was able to cluster spectra from...

Read More


From monoclonal to polyclonal antibodies with VALENS
19 Jan 2015

From monoclonal to polyclonal antibodies with VALENS

Valens is a powerful tool for de novo sequencing of monoclonal antibodies. At PepTalk 2015, we explored the capability of Valens to sequence mixtures of monoclonal antibodies, which are of great relevance in the development of therapeutics. From a simulated mixture of 3 monoclonal antibodies, Valens was able to recover 88% of the sequence of the most abundant form. We are excited by the prospect...

Read More